Dynavax says FDA rejects its hepatitis B vaccine

(Reuters) - Dynavax Technologies Corp said on Monday the U.S. Food and Drug Administration had rejected the marketing application for its hepatitis B vaccine Heplisav-B, sending the company's shares tumbling 44 percent in premarket trading.